Natixis Evolus, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Evolus, Inc. stock. As of the latest transaction made, Natixis holds 5,293 shares of EOLS stock, worth $62,880. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,293
Previous 6,275
15.65%
Holding current value
$62,880
Previous $68,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EOLS
# of Institutions
169Shares Held
47.8MCall Options Held
130KPut Options Held
51K-
Perceptive Advisors LLC New York, NY5.36MShares$63.6 Million2.27% of portfolio
-
Tang Capital Management LLC San Diego, CA4.85MShares$57.6 Million6.69% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$47.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.2MShares$38 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$33.6 Million2.72% of portfolio
About Evolus, Inc.
- Ticker EOLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 56,094,800
- Market Cap $666M
- Description
- Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...